Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 8, 2018
Reporting Period: First quarter ended March 31, 2018
This filing serves as a notification that the Company issued a press release regarding its financial results for the first quarter of 2018. The detailed financial data is contained in the press release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text is a cover document for the Form 8-K and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the attached press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms the issuance of results for the quarter ended March 31, 2018.
Guidance, Outlook, and Risks
- Conference Call: The Company scheduled a conference call for May 9, 2018, at 9:00 a.m. Eastern Time to present the financial results. A live webcast was available on the Company's website.
- Forward-Looking Statements: The filing contains forward-looking statements regarding plans, strategies, and intentions. These are subject to risks and uncertainties, including those detailed in Item 1A ("Risk Factors") of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017.
- Legal Disclaimer: Information in Item 2.02 is "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, limiting liability and incorporation by reference.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific Q1 2018 revenue, net loss, and cash position figures.
- Verify the details of the conference call held on May 9, 2018, for management commentary on the results.
- Consult the Form 10-K filed on March 1, 2018, for a comprehensive list of risk factors affecting forward-looking statements.
- Confirm the Company's status as an emerging growth company and any related election regarding extended transition periods for accounting standards.